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Patients suffering from head and neck squamous cell carcinoma (HNSCC) 
encounter low survival while managing current aggressive therapies that cause significant 
morbidity. Nutraceuticals are diet-derived compounds with few known side effects. 
However, limited antitumor efficacy has restricted their use for cancer therapy. In this 
work, we examined combined plant compounds, established a combination therapy that 
was more potent than its singular components, and delineated its mechanism of action. 
Curcumin is a yellow polyphenol that is derived from the rhizome of turmeric (Curcuma 
longa). It is known to influence multiple cellular processes. Likewise, harmine, a beta-
carboline alkaloid found in Peganum harmala, and isovanillin, a phenolic aldehyde isomer 
of vanilla, have shown antitumor activity. We tested the antitumor efficacy of three 
formulation: GZ17-S (combined plant extracts from Arum palaestinum, R Peganum 
harmala and Curcuma longa); GZ17-05.00 (16 synthetic components of GZ17-S); and 
GZ17-06.02 (chemically synthesized curcumin, harmine and isovanillin).  We tested the 
formulations on HNSCC progression. Specifically, we carried out in vitro studies on 
HNSCC proliferation, migration, invasion, angiogenesis, apoptosis, and macrophage 
viability and infiltration into the tumor. We demonstrated that GZ17-06.02 was most 
effective in attenuating in vitro parameters of HNSCC progression. Further, GZ17-06.02 
potentiated the efficacy of cisplatin and radiation therapy. We demonstrate that GZ17-
06.02 has multiple molecular targets including EGFR, ERK1/2, and AKT. We used 
molecular docking analyses to validate that GZ17-06.02 components bound at distinct 
binding sites on these targets. Finally, we demonstrated that GZ17-06.02 significantly 
inhibited the growth of established HNSCC cell lines, patient-derived xenografts, and 
murine syngeneic tumors (P<0.001). We demonstrated GZ17-06.02 as a highly effective 
plant extract combination for HNSCC. These studies provide rationale for clinical testing 
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Chapter I: Introduction 
 
Head and neck squamous cell carcinoma (HNSCC) is an illness that is severely 
burdensome, causing great morbidity and mortality. Globally, 500,000 new individuals 
are diagnosed every year [1]. Worldwide and domestically the incidence of HNSCC has 
persistently remained unchanged over the past three decades. The gravity of this 
disease is exemplified by the five-year survival rate that remains below 50% [2]. The 
current treatment mainstays are surgery, chemotherapy, and radiotherapy. While these 
treatment strategies can be effective, they often leave the patient to bear significant 
morbidity. The heavy cost of treatment demands better, less enervating therapeutic 
options.  
Histologically, head and neck cancers originate from the mucosal surfaces of the 
larynx, pharynx and oral cavity. Approximately, 90% occur from proliferative squamous 
cells (HNSCC). The other 10% of head and neck cancers originate from salivary glands, 
and an even smaller percentage consists of sarcomas [3], paragangliomas [4], and 
neuroblastomas [5]. Not only is HNSCC the most common head and neck cancer, it is 
also the most lethal.  
The risk factors of HNSCC are tobacco and alcohol consumption, which have 
been commonly associated with the disease. Increasingly, human papilloma virus 
(HPV) associated HNSCC is on the rise.  The risk of HNSCC is dramatically increased 
with greater than 30 g ethanol/day, which is comparable to three “standard” drinks [6]) 
(multivariable adjusted incidence rate ratio: 6.39) [7]. Tobacco use increases the risk of 
hypo/oropharyngeal caner and laryngeal cancer (multivariable adjusted incidence rate 
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ratio: 8.53 and 8.07, respectively)[7]. As the smoking rates are declining globally, there 
has been a substantial decrease of non-HPV oropharyngeal carcinoma by 50% since 
the late 80’s [8].  
However, there has been a two-fold increase in HPV positive oropharyngeal 
carcinoma cases in the same time period [8]. Associative HPV factors include higher 
number of lifetime sexual partners and marijuana use, but not alcohol or tobacco usage 
[9]. Squamous epithelium of the head and neck, anus, and cervix are especially 
susceptible to HPV.  
The oncogenic types HPV-16, HPV-18, HPV-31, and HPV-33 are sexually 
transmitted viruses that can transform infected cells. 
 Type 16 HPV are responsible for the vast majority of HPV related HNSCC. In 
most individuals, the virus clears. However, in those patients that fail to mount an 
adequate immune response, HPV a non-enveloped, DNA virus incorporates into the 
host genome, transforming the host cell with the E6 and E7 proteins that inhibit tumor 
suppressor, p53 and retinoblastoma (Rb), respectively[10]. Additionally, p16 binds and 
inhibits cyclin dependent kinase 4 and 6, thereby blocking the catalytic activity of CDK-
cyclin D1 that are required for Rb phosphorylation; this initiates cell cycle arrest [11]. 
These tumors present differently and have better clinical outcomes that do carcinogen-
induced HNSCC. However, HPV vaccines are 90-100% effective in preventing HPV 
infections that lead to precancerous lesions [12]. Thus, global HPV related cancers are 
projected to be dramatically reduced by the year 2050 [13]. 
Globally, other factors that contribute to HNSCC development include naswar (a 
mix of tobacco, calcium hydroxide, ash of plants, spices and oil) sniffing/dipping,  Betel 
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(Areca) nut chewing, Khat chewing, and Maté [14]. These factors are all dose 
dependent and have been shown to have mutagenic properties. Finally, the Epstein 
Barr virus can induce cellular proliferation of the tonsil, oropharynx, and salivary gland. 
The nasopharynx is the commonly affected [15]. Nevertheless, HPV, tobacco, and 
alcohol comprise the vast majority inciting factors. 
 















Figure 1-1: HPV cellularly transforms head and neck cancer cells. Following HPV infection, the viral 
oncoproteins E7 and E6 alter pRb and p53 respectively. Alteration of pRb inhibits E2F, a tumor 
suppressing transcription factor, leading to DNA synthesis. E2F alteration leads to increased p14, which 
then alters the production of HDM2, a ubiquitin ligase that suppress the p53. This in turn yield nuclear 
export and degradation of tumor suppressor and cell cycle progression. Inhibition of p53 directly by the 
E6 oncoprotein causes cell cycle arrest and apoptosis.    
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HNSCC patients are usually above the age of 40, from unspecified 
socioeconomic backgrounds, and have a higher male to female ratio of 3:1 (HPV 
negative); 8:1 (HPV positive) [16]. In North America 56% of HNSCC cases are HPV 
positive [17]. HPV-positive HNSCC patients are characteristically middle aged, non-
smoking white men from higher socioeconomic status and have a history of multiple 
sexual partners [18]. 
Patients often present with lesions in the oral cavity that are self-discovered or 
clinically uncovered. Most of these lesions are easily noticed during examination. 
Thickening of the mucosa, a painful or painless mass, or ulcer accompanied by 
odynophagia and dysphagia are common clinical manifestations. However, lesions of 
the larynx are much more difficult to discover, in part because of their hard-to-self-
visualize location in the body. In the larynx, patients often present with shortness of 
breath, hoarseness, stridor, and dysphagia [19].  
Tumor staging, tobacco use, and race are all considered when prognosis is 
determined at initial diagnosis [20]. The American Joint Committee on Cancer has laid 
forth the HNSCC tumor staging guidelines. Prognosis is broken into categories ranging 
from best prognosis, 0, and worst, IV, depending on tumor (T) characteristics, nodal (N) 
characteristics, and distant metastasis (M). HPV positive HNSCC is specially 
considered using p16 immunohistochemistry (IHC) [21].  
Other factors that influence prognosis are race and environment. Black non-
Hispanics and present tobacco users have much worse outcomes [20].  Nonetheless, 
early detection provides better outcomes to patients. However, at initial diagnosis, over 
40% of patients have advanced disease with regional nodal involvement [16].  
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HNSCC initiates with an intraepithelial proliferation of squamous cells. This 
cellular proliferation may become evident as a white patch or plaque (leukoplakia) that 
cannot be easily removed by rubbing [22].  
HNSCC is a highly recurrent disease. Up to 30% of patients develop distant 
metastases, while the majority of patients develop some form of recurrent disease [23]. 
Field cancerization in HNSCC is caused by carcinogenic risk factors. This field 
cancerization causes the development of multiple primary tumors in the same anatomic 
region [24]. In concurrence with this phenomenon, epithelia surrounding the carcinoma 
undergoes genetic alterations [25]. Notwithstanding, targeted radiotherapy and 
sufficiently resected tumors do not account for the dysplastic field of carcinogen 
exposure, which facilitates a high rate of recurrence.  
The five-year survival rate of HNSCC patients upon initial diagnosis is less than 
50%. Even such poor outcomes demand a multidisciplinary approach including head 
and neck surgeons, medical oncologists, radiation oncologists, with support from 
speech therapists, social workers, psychologists, and dieticians.  
Current Therapy 
Patient characteristics, site, and stage are determinant factors that influence the 
use of the three treatment modalities of chemotherapy, radiation, and surgery. In early 
disease stage, surgery and radiation are the primary treatments. Chemotherapy is used 
in combination with other modalities across multiple disease stages. Surgery has had 
the best treatment outcome for many years which lead to the development of the 
surgeon’s stature as leader of the care team. However, microscopic disease that is not 
easily assessed or treated with surgery are treated with chemotherapy and radiation. 
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Radiotherapy is the primary treatment for HPV+ tumors. Each treatment option offers 
distinct advantages alongside distinct morbidities.  
Surgery 
 For nearly all head and neck tumors, surgery provides the best control of the 
disease. Surgical technique and approach varies depending on tumor location and local 
aggressiveness [26]. Retaining function and cosmetic outcome are surgical 
considerations. Reconstructive surgery has advanced in the last 25 years, offering 
surgeons more latitude in establishing free margins [23]. Patients are more likely to 
experience minimal functional impacts with negative margins and proper reconstruction.  
 However, as the extent of the surgical procedure increases, as does the 
morbidity of the patient. Immediate risks following surgery are hemorrhage, aspiration 
pneumonia, and pulmonary embolism [23]. Following surgery, a pain management is 
implemented. Advanced disease usually requires large surgical margins, which can lead 
to disfiguration. Secondary reconstructive surgery may follow initial tumor resection. For 
early stage patients, the single modality of surgery can provide a cure rate of up to 90% 
[23]. 
Radiotherapy 
Ionizing radiation damages cells directly through ionizing of target molecules and 
indirectly by generating reactive oxygen species from water [27]. In early stage HNSCC, 
single modality radiotherapy is often effective and can yield cure rates between 70-90% 
[28]. Nevertheless, late stage disease does not have such cure rates. Advanced 
disease can expect only 50% tumor control with radiotherapy alone, leaving the five-
year survival rate at just 30% [28]. Side effects of radiation therapy are xerostomia, 
radiation-induced fibrosis, trismus, and osteoradionecrosis [29].  
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Chemotherapy 
 The last four decades have seen a substantial development of chemotherapy 
treatment for head and neck patients. Cisplatin was approved in 1978, which gave 
physicians options beyond the once standard palliative treatment with bleomycin and 
methotrexate [30, 31]. While there was a tumoral response from bleomycin and 
methotrexate, these drugs offered no improvement in overall survival. Alternatively, 
while cisplatin alone did not improve overall survival or response rate [32], it did confer 
the benefit of in combination treatments [33].  Cisplatin improves median survival by 1-2 
months compared to supportive care alone [34]. Cisplatin in combination with taxanes 
or fluorouracil improve response rate of non-targeted chemotherapies [35]. Three 
decades after cisplatin was introduced, targeted EGFR therapy cetuximab, a 
monoclonal antibody, added another 2 months to the overall survival of cytotoxic 
therapy [36].  
Immunotherapy has been the only area of improved overall survival in head and 
neck cancer patients since the approval of cetuximab over 10 years ago. The T-cell 
suppressive receptor, programmed death-1 (PD-1), is activated by programmed death 
ligands (PD-L1 and PD-L2) of the head and neck tumor cells, thereby evading the 
immune system [37]. While numerous clinical predictive diagnostics are currently under 
investigation, PD-L1 positivity testing by immunohistochemistry is widely accepted in 
head and neck cancer. This testing can be onerous as only membranous tumor tissues 
are considered significant, which may not be readily available following surgery[38]. For 
certain patients, nivolumab and pembrolizumab, both monoclonal antibodies targeting 
PD-1, improved overall survival [39, 40]. These targeted therapies might indicate an 
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avenue of further scientific exploration that will improve the lives of head and neck 
cancer patients.  
Early stage disease is easily treated with surgery and radiation with good 
outcomes. However, advanced stage tumors generally require surgery, radiation, and 
chemotherapy. If the disease progresses, PD-1 targeted immunotherapies can be a 
second-line treatment. While these therapies are borne of more than five decades of 
scientific work, the best care will only improve overall survival by months, not years. 
Currently successful treatment, especially in later stages, requires a high morbidity cost. 
Likewise, chemotherapeutic agents currently available to treat head and neck cancer 
are highly toxic, destroy off-target cells, and cause the patient further illness. There is a 
current need for agents that are efficacious, cause few side effects, and are generally 













Chapter II: Plant Compounds as Head and Neck Treatment  
 
A brief history of food as medicine 
Nearly 5000 years ago the oldest written evidence of plants being used as 
medicine was recorded on a Sumerian clay slab from Nagpur. The slab described a 12 
medicinal recipes containing over 250 plants, some of them were alkaloid like poppy, 
mandrake, and henbane [41]. Empedocles of Agrigetum (490-430 B.C.E.) was the first 
to introduce the idea that balanced food consumption could treat disease, leading to 
humoral theory [41]. Hippocrates of Kos, the “Father of Medicine,” while being the first 
major proponent of medicine as an independent profession, implementing the study of 
clinical medicine, and summarizing medical knowledge of previous schools is also 
credited with the phrase “Let food be thy medicine, and medicine be thy food”[42]. 
Indeed, early medical practitioners in the same vein were known to adjust diet based on 
the illness presented. Although an aphorism, the successful treatment of many patients 
in ancient medicine was likely due to meeting dietary inadequacies, not a direct 
interaction between food and disease [43]. The first century Greek surgeon Galen 
interpreted the work of Hippocrates in his practice and training. He implemented 
Hippocrates’ humoral theory (the belief that the body contained “humors”, and that if not 
in balance would produce disease and poor temperament [44]), prescribing food 
depending on the humor responsible for the affliction [45]. Galen’s practice and teaching 
influenced medicine for the next 1,300 years [46]. Humoral theory was not seriously 
challenged until the 16th century by physicians. In 1628 William Harvey published De 
Motu Cordus (Latin for “An Anatomical Exercise on the Motion of the Heard and Blood 
in Living Beings”), which came in direct conflict with humoral theory and centuries of 
Galenic medicine [47]. In 1858, Rudolf Virchow published Cellular Pathology [48], 
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known as the first systematic pathology text, that contributed to cell theory and ended 
humoral theory entirely, and brought the decline of food as medicine. 
 Following the rise of the industrial revolution in the West, food as medicine 
slipped out of medicine and into the fringes of alternative medicine, and lacked general 
acceptance in the medical profession [49]. However, following the discovery and 
classification of vitamins, food and naturally derived compounds were beginning to gain 
attention once again in the science community [50]. In the field of cancer, the discovery 
of paclitaxel in 1962 moved forward treatment options for many types of cancer. 
Paclitaxel, a microtubule binding agent, was initially harvested from the bark of yew 
trees [51]. Vincristine, another tubule targeting drug, was first isolated in 1961 from 
flowering Vinca plants. Again this added to the regime of drugs available to treat 
Hodgkin’s lymphoma and non-Hodgkin’s lymphoma [52]. As production of 
chemotherapies slowed during the latter half of the 20th century, an interest in anecdotal 
evidence in non-Western treatments of cancer rose [53]. Eastern medicine, middle east 
folk medicine, and Ayurvedic medicine commonly prescribe many roots, seeds, and 
barks based treatments [53].  
Plants Compounds and Head and Neck Cancer  
In 1989 Stephen D. Felice coined the term nutraceutical (a portmanteau of nutrition 
and pharmaceutical) in an effort to more systematically study and classify plant and 
food based medicine [54]. Nutraceutical is broadly defined as any substance that can be 
considered a food or part of a food and provides medical or health benefits including the 
treatment and prevention of disease [53]. Nutraceuticals have long been considered 
safe and generally acceptable. Some of the first nutraceuticals to be tested in the 
treatment of HNSCC with antitumor efficacy include genistein [55], resveratrol [56], 
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luteolin [57], and isothiocyanate [58]. Indeed, lycopene [59], vitamin A derivatives [31], 
green tea extract [60], curcumin [61], and soybean extract have all undergone HNSCC 
clinical trials [62]. These studies are limited in that they are preventive studies, not 
treatment of the disease directly.  
There are no previous studies investigating a combination of natural compounds in 
the treatment of HNSCC. Combining cancer treatment agents is proven to reduce side 
effects of single agents and have additive anticancer effects. This spurred interest in 
investigating combinations of nutraceuticals in the treatment of HNSCC, which may 
allow for improved efficacy and lower drug concentrations. 
Curcumin 
Curcuma longa is a heavily studied plant[63]. Curcumin, the active ingredient, 
inhibits nuclear factor-κB (NF-κB), epidermal growth factor receptor (EGFR), mitogen 
activated protein kinase (MAPK), and vascular endothelial growth factor (VEGF) (Fig 2-
1) [64-66]. However, curcumin also has poor bioavailability [67]. This has developed 
interest in curcumin analogs and nanoparticle encapsulation to increase bioavailability 
[68]. Additionally, combining curcumin with different nutraceuticals potentiates efficacy 
[69], and the combination of curcumin provides additive benefit to chemotherapeutics 
[70]. Crooker et al reviewed natural compounds in the treatment of HNSCC with 
particular focus on curcumin. HNSCC is shown to have multiple targets affected by 




















Figure 2-1: Curcumin acting on targets in HNSCC. Curcumin blocks EGFR, VEGFR, NF-κB and MAPK 
which suppresses tumor growth, cellular proliferation, metastasis, angiogenesis and cytokine Il-6 and Il-8. 




Arum palaestinum  
 Arum palaestinum is widely cultivated in Palestine, and has been used to treat 
cancer in Palestine for many years [71]. Extracts in ethanol of Arum palaestinum have 
demonstrated antitumor efficacy in prostate cancer, breast cancer, and leukemia [63, 












































Figure 2-2: Multiple nutraceuticals act on tumor suppressors, transcription factors, and signaling 









Peganum harmala contain alkaloids that are known to have a wide range of 
medicinal properties. The main component, harmine, demonstrates anti-tumor effects 
and inhibits monoamine oxidase [73]. Harmine has been shown to intercalate with DNA 
[74], and prevents chemotherapy resistance by interfering with drug efflux [75]. Harmine 
has little effect on normal cell lines while decreasing proliferation of various tumor lines 
[76].  
While chemotherapies are often given to patients in combination, a systematic 
study of HNSCC response to nutraceuticals given in combination has yet to be 
investigated. The purpose of this study was to assess whether a potentiated or additive 
effect could be obtained by combining nutraceuticals. The previous work on curcumin in 
combination with cancer therapy [69] [70] was used as the starting point and included 
Arum palaestinum and Peganum harmala for their purported anti-tumor activity in 
HNSCC. The plant combination of dried extracts of three plants (GZ17-S), a synthetic 
variety of the extract (GZ17-5.0) and the three major anti-tumor synthetic compounds 
found in the original plants (GZ17-6.02) were assessed and compared. The results 
demonstrated a highly effective nutraceutical combination for treating HNSCC, and the 
proposed combination as more potent than their singular agents in preclinical models. 
The mechanism of action and evidence of a useful biomarker for future clinical study 







Chapter III: Methods 
Sections of this chapter have been previously published as an open access article and 
are included here with adaptations with permission.  Vishwakarma, V., et al., Potent 
Antitumor Effects of a Combination of Three Nutraceutical Compounds. Sci Rep, 2018. 
8(1): p. 12163. 
Cells and Reagents 
Well characterized HNSCC cell lines were used in this study[77]. HNSCC lines 
OSC19, HN5 and UM-SCC-1, Het1A a cancer-free, immortalized, esophageal line, 
glioblastoma line U87, and murine SCCvII/SF cultured in increased glucose DMEM 
(Corning, NY, USA) with 10% heat-inactivated fetal-bovine (FBS). Lung cancer lines A549 
and 201T cultured in Hams F12K media (for A549) and Basal Eagle Media (for 201T) 
both augmented with 10% FBS. A maximum of 10-12 passages were used while growing 
all cell lines. HUVECs were cultured in endothelial basal medium-2 augmented with 
endothelial growth media-2 SingleQuot Kit (Lonza, Basel, Switzerland) using 
manufacturer’s instructions. Primary HNSCC tumor tissue was collected through the 
Biospecimen Repository Core at the University of Kansas Cancer Center with written 
informed consent from patients, using protocols approved by the Institutional Review 
Boards at the University of Kansas Medical Center (KUMC). 
The plant compound, GZ17-S, was provided by Genzada Pharmaceuticals (Sterling, KS) 
and prepared by combining curcumin, Arum Palaestinum, and Peganum harmala seeds, 
by means of a previously published protocol [78]. GZ17-5.00 formulation (Afaya Plus) 
was provided by Genzada Pharmaceuticals, and prepared by combining nutraceutical 
components: curcumin, piperonal, harmine (Indofine, Hillsborough, NJ), hydroxymethyl 
furfual, limonene, citraconic anhydride, benzyl nitrile, methylpyroglutamate, and 
isovanillin (all components from Sigma-Aldrich, St. Louis, MO). In the extraction 
procedure, linolenic acid (TCI Chemicals, Portland, OR), iodine solution (LabChem Inc, 
Zelienople, PA), diallyldisulfide (Sigma-Aldrich), and betasitosterol (MP Biomedicals, 
Santa Ana, CA) were used [79]. 
GZ17-6.02 was prepared by combining harmine, isovanillin, and curcumin (Sigma-
Aldrich) (Supplemental Table 1). Cisplatin was obtained from Fresenius Kabi (purchased 
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by KUMC Pharmacy, Kansas City, KS). Tofacitinib was purchased from Selleckchem 
(Houston, TX). Recombinant human epidermal growth factor receptor (EGFR) was 
purchased from Fisher Scientific (Gibco, PHG0314, Waltham, MA) [79]. 
 
Cytotoxicity Assay  
Cells (4x103 cells/well, 96-well plate) were treated in triplicate with GZ17-
formulations at various concentrations, and cell proliferation assessed using CyQUANT 
assay kit (Life Technologies, Waltham, MA) using the manufacturer’s instructions. After 
72 h. ED50 calculated using non-linear curve fit with GraphPad Prism software version 
6.03 (GraphPad Software Inc., San Diego, CA) [79].  
HNSCC cells treated with cisplatin (4µM), GZ17-6.02 (ED50 of respective cell type), 
combination cisplatin and GZ17-6.02, or vehicle control for 72 h. Cell viability assessed 
using CyQUANT.  
To assess the efficacy of GZ17-06.02 to potentiate the effects of radiation on HNSCC, 
OSC19 (2x103 cells/well in 96-well plates) were treated with 3, 6, and 9 Gy of radiation. 
Plates were exposed to gamma radiation (J.L. Shepherd and Associates Mark I Model 
68A cesium-137 source irradiator; dose rate = 2.9 Gy/min). Media was aspirated, and 
cells were treated with GZ17-06.02 ED50 concentration or vehicle control in DMEM with 
10% FBS [79]. 
 
Migration and invasion assay 
Cells (2 x 104 cells per insert) were seeded in trans-well inserts with 8 μm pores 
(Becton Dickinson, Franklin Lakes, NJ). For invasion assay, a layer of diluted Matrigel 
(2 mg/ml) in DMEM (BD Biosciences, San Jose, CA) was placed in the insert.  Cells in 
serum-free media were seeded on top of Matrigel layer for invasion or directly onto 
insert for migration assay. The inserts were placed in duplicate holding-wells containing 
GZ17-formulations (ED50) in complete media for 24 h. Treated cells were plated in 
parallel to assess viability using CyQuant. The number of cells that moved to other side 
of membrane were counted after fixation and staining with Hema3 kit (Fisher Scientific). 
The numbers of invading or migrating cells were normalized to cell viability [79]. 
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Tubule Formation Assay  
HUVEC cell lines were plated on Matrigel in triplicate with GZ17-6.02 or vehicle 
control (15 x 103 cells/well of 96-well plate). After 6 hours, images were taken from 5 
random fields per well. Images were analyzed using Pipeline software version 1.4 
(Medical College of Wisconsin, Milwaukee, WI) according to published instructions to 
quantify total tube length [80]. 
 
Macrophage infiltration and viability 
To test the effect of GZ17-formulations in attenuation of macrophage infiltration 
into the tumor, we used the metastatic mimetic device (MMD) as previously described 
[81]. 2.5 x 105 OSC19 cells were embedded in rat tail collagen in the MMD and allowed 
to gel overnight. 5x105 Thp1 were plated into the outer chamber of the device in serum 
containing medium. The collagen plugs were quantified using ImageJ software. Viability 
of Thp1 cells were assessed by counting cells on a hemocytometer using trypan blue dye 
exclusion. HNSCC cell viability was assessed by imaging cells stained with 0.1 µM 
Calcein AM dye for 60 min at 37°C in the dark [79]. 
 
Human phospho-kinase profiler array  
Human phospho-kinase array (ARY003, Proteome Profiler™, R&D Systems, 
Minneapolis, MN) was used to identify signaling molecules regulated by GZ17-
formulations per manufacturer’s instructions. Membranes imaged by autoradiography, 
and ImageJ quantified signal intensity [79].  
 
Immunoblotting 
Cells (3 x 105 cells/60 mm dish) were treated with GZ17-formulations (ED50) for 72 h 
and lysed in RIPA buffer containing protease/phosphatase inhibitors (cOmplete, Mini, 
Roche, Indianapolis, IN). Inhibition of EGF was stimulated via cell starvation for 48 hours, 
and then treated with GZ17-6.02 (ED50) for 2 hours. EGF (10 ng/mL) was applied for 5 m, 
and then cells were harvested in RIPA buffer containing protease/phosphatase inhibitors 
on ice. Proteins were separated by SDS-PAGE, transferred onto nitrocellulose 
membranes, and probed with p-ERK1/2 (p44/42-pMAPK; Thr202/Tyr204), total ERK1/2, 
cleaved PARP, caspase-3 (Cell Signaling, Danvers, MA) and β-tubulin (Fisher). 
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Immunoreactivity was detected using anti-mouse or anti-rabbit IgG conjugated to Dylight-
680 or -800 (Fisher). Protein bands were detected using Li-Cor Odyssey protein imaging 
system (Li-Cor Biotechnology, Lincoln, NE) and quantified using ImageJ [79].  
 
Computational Molecular Docking 
Ligands designed using ACD/ChemSketch software (ACDlabs, Ontario, Canada). 
Crystal structures of proteins downloaded from RCSB-Protein Data Bank 
(http://www.rcsb.org/pdb/home/home.do). AutoDock-Vina was employed for molecular 
docking using protein and ligand information. During the docking procedure, proteins 
were considered as rigid and ligands as flexible. The docking pose with lowest binding 
energy and highest binding affinity was aligned with the protein structure [79].  
 
Cell cycle analysis 
OSC-19 cells (2x105) were treated in triplicate with ED50 concentrations of GZ17-
formulations for 72 h. Cells were washed with PBS, fixed with 70% ethanol, stained with 
propidium iodide (0.02mg/ml in PBS with 0.1% TritonX-100) (Life Technologies), and 
subjected to cell cycle analysis using Accuri C6 Flow Cytometer (BD Biosciences). Data 
were analyzed using the software provided by the manufacturer and samples analyzed 
in triplicate [79]. 
 
In vivo studies 
Animal care was in strict compliance with IACUC guidelines at the University of 
Kansas Medical Center. Mice were housed in individually ventilated cages in a sterile 
environment, and all experimental work was conducted during daytime hours. A blind 
observer assessed all measured outcomes. To assess in vivo antitumor efficacy of GZ17-
formulations, 1 x 106 HNSCC (OSC19) cells were injected subcutaneously into the flank 
of athymic nude-Foxn1nu mice (Harlan Sprague Dawley, Indianapolis, IN). Tumor bearing 
mice were randomized when tumor volume reached 5.0 mm3. Mice were treated with 15 
mg/kg/day of GZ17-formulations or with saline control by 50 µL intratumoral 
administration once daily, five days/week. Tumor diameters were measured in two 
perpendicular dimensions and volume calculated as previously described, briefly (tumor 
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volume = long dimension x (short dimension)^2 x 0.52) [82]. Animals were euthanized by 
CO2 asphyxiation followed by pneumothorax [79].  
A syngeneic HNSCC model was used [83]. 1 x 106 SCC/vII cells were inoculated 
in the flank of C3H mice to assess GZ17-6.02 in immunocompetent hosts. Tumors were 
established for 6 days, and mice randomized into treatment groups (n=10/group). 
Treatment was delivered suspended in 1% carboxymethylcellulose (CMC) by oral gavage 
(100 mg/kg/day). Mouse weight and tumor volumes were measured three times per week 
[79]. 
To determine GZ17-6.02 efficacy in patient-derived HNSCC xenografts, 35 mg of 
primary HNSCC tissue was surgically implanted subcutaneously into flanks of athymic 
nude-Foxn1nu mice under inhalant isofluorane anesthesia. Intraoperatively animals were 
administered analgesic Buprenorphine SR at 0.3 mg/kg and tofacitnib (to reduce natural 
killer cell counts) at 15 mg/kg via subcutaneous injections. Established tumors were 
passaged twice through mice before implantation for study.  Tumor bearing mice were 
randomized in treatment groups (n=10/group). Mice were treated with 30 mg/kg GZ17-
6.02 or 1% carboxymethycellulose control via oral gavage once daily, five days/week. On 
treatment day 8, the dose was increased to 50 mg/kg/day to improve antitumoral 
response. As PDX models have variable growth rates, data presented for in vivo studies 




All results are cumulative from three independent experiments. For in vitro and in vivo 
experiments, unless otherwise indicated. Data analyzed using nonparametric Mann-





Chapter IV: Results 
Sections of this chapter have been previously published as an open access article and 
are included here with adaptations with permission.  Vishwakarma, V., et al., Potent 
Antitumor Effects of a Combination of Three Nutraceutical Compounds. Sci Rep, 2018. 
8(1): p. 12163. 
Combining curcumin, harmine, and isovanillin demonstrates potent cytotoxicity in 
multiple cell lines.  
 
 
Varying concentrations of GZ17-formulations were tested on HNSCC cell lines 
(0, 0.78125, 1.5625, 3.125, 6.25, 12.5, 25, 50 µg/mL) to determine the dose response to 
different formulations. GZ17-6.02 was the most cytotoxic (OSC19 cell ED50 = 11.85 
μg/ml; UM-SCC-1 cell ED50 = 13.03 μg/ml; HN5 cell ED50 = 13.73 μg/ml) as compared 
to GZ17-5.00 and GZ17-S (Fig. 4-1 A). At 50 ug/mL no formula displayed complete cell 
killing, as such ED50 concentration was used for further studies. In Het1A cell line, a 
non-cancerous immortalized esophageal line, a higher ED50  was observed (Fig. 4-1B). 
To eliminate the possibility these effects were anomalous to HNSCC cell lines, 
the proliferation of glioblastoma line U87, and lung cancer lines 201 T and A549 was 
assessed. GZ17-6.02 was cytotoxic in these cell lines congruent to the HNSCC lines 
tested (Fig. 4-1C). Thus, these results show that a combination of synthetic plant 





Figure 4-1: GZ17 is cytotoxic to HNSCC and potentiates effects compared to 






































Figure 4-1: (A) OSC19 (4x103 cells/well in triplicate) were treated with different concentrations of GZ17-
6.02, -5.0, and -S. Effective dose (ED50) was calculated with non-linear curve fit using the software 
GraphPad Prism. Cumulative data signifies three separate experimental repeats and error bars represent 
± SEM. (B) Het1A (4x103 cells/well in triplicate) were treated with different concentrations of GZ17-6.02, -
5.0, and -S. Effective dose (ED50) was calculated with non-linear curve fit using the software GraphPad 
Prism. Cumulative data signifies three separate experimental repeats and error bars represent ± SEM. (. 
(C) Glioblastoma (U87, and lung cancer lines (21T and A549) were treated with different concentrations 
of GZ17-6.02 to assess ED50 concentrations [79]. 
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GZ17-6.02 and -05.00 induce apoptosis through PARP cleavage and caspase-3 
activation. 
 HNSCC cells were treated for 72 hours at the ED50 dose. GZ17-05.00 and GZ17 
induced significant apoptosis (24% and 22%, respectively, P < 0.05) demonstrated by 
the sub G0 fraction of cell cycle analysis in treated cells (Fig. 4-2 A). Poly-ADP ribose 
polymerase (PARP) and caspase – 3 were assessed using immunoblot. After GZ17 – 
6.02 and GZ17 – 05.00 treatments at ED50 concentrations, HNSCC cells showed 
increase cleaved PARP and decreased caspase – 3 (Figure. 4-2 B), indicating 
treatment-induced apoptosis.  
 
 Figure 4-2: GZ17 treatments induce apoptosis via cleaved PARP cleavage and 
caspase-3 activation in HNSCC cells  
  
 











Figure: 4-2: (A) HNSCC cells (OSC19; 2 × 105 cells) were treated with vehicle control or ED50 
concentrations of GZ17-6.02, -05.00 or –S for 72 h and analyzed via flow cytometry. The percentage of 
cells in different cell cycle stages is represented of each treatment of GZ17 formulation at ED50 
concentration. The graph represents cumulative results from three independent experiments. (B) 
Representative immunoblot of apoptotic markers cleaved-PARP and caspase-3. β-tubulin levels show 





GZ17-6.02 mitigates migration and invasion of HNSCC cells, and endothelial cell tubule 
formation. 
The effects of GZ17-formulations on HNSCC migration and invasion were 
assessed. GZ17-6.02 (ED50 dose) was most effective in significantly inhibiting 
migration (p < 0.0001, Fig. 4-3A); and invasion (p = 0.0003, Fig. 4-3B). In addition, the 
inhibitory effects of GZ17-6.02 against glioblastoma and lung cancer cell line migration 
and invasion were assessed, and observed significant reductions in U87 (Fig. 4-3C), 
201T (Fig. 4-3D), and A549 (Fig. 4-3E) migration and invasion. 
Macrophage infiltration is often associated with an inflammatory reaction, and 
tumor-associated macrophages may facilitate tumor progression. A 3-dimensional cell 
culture device called the metastatic mimetic device (MMD) was used to assess 
macrophage infiltration into tumors when treated with GZ17-6.02 or vehicle control [84]. 
HNSCC cells embedded in a collagen matrix were subjected to macrophage infiltration 
in the MMD in the presence of vehicle control or GZ17-6.02. GZ17-6.02 effectively 
reduced macrophage survival (Fig. 4-3F) and subsequently infiltration through the 
collagen plugs. These functional assays demonstrate that GZ17- 6.02 significantly 
inhibited in vitro tumor progression.  
Angiogenesis is the process through which HNSCC forms new blood vessels 
from pre-existing vessels, allowing access to nutrients required for the survival of tumor 
cells. However, no antiangiogenic therapies are approved for use in HNSCC28. We 
tested the efficacy of GZ17-6.02 (ED50 dose) to inhibit endothelial tubule formation, an 




Figure 4-3: GZ17-6.02 effectively inhibits migration and invasion of HNSCC cells, 
and endothelial cell tubule formation 
 































Figure 2. (A, B) HNSCC cells (OSC19; 2 × 103 cells/ well, plated in triplicate) were treated with ED50 
concentrations of GZ17-6.02, -05.00 or -S, or vehicle control. Cell migration and invasion was determined 
at 24 h. The number of cells that (A) migrated or (B) invaded were counted and normalized to the cell 
viability. Percent migration or invasion compared to the vehicle control is shown in the graphs. Sum data 
represents three individual experimental repeats and error bars represent ± SEM. (C,D,E) Glioblastoma 
(U87), and (D and E) lung cancer (201T and A549) were determined for GZ17-6.02 inhibition of migration 
and invasion. Sum data represents three individual experimental repeats and error bars represent ± SEM. 
(F) GZ17- 6.02 inhibits tumor-promoting macrophage survival. Macrophage cell line Thp1 were treated 
with 60 μg/ml GZ17-6.02 for 48 h. Viable cells were counted using trypan blue dye exclusion. Graph 
represents sum results from five individual experiments and error bars represent ± SEM. (G) GZ17-6.02 
modulates the angiogenic potential of HUVEC in vitro. HUVEC cells were treated with the ED50 dose 
(derived from OSC19) of GZ17- 6.02 and imaged 6 h after treatment and tubule formation was 
determined. Total tube length analyzed using Pipeline software from 15 random fields from each repeat, 
and normalized to vehicle control treated cells (VC). Sum data represents three individual experimental 
repeats and error bars represent ± SEM [79]. 
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GZ17 -formulations modulate signaling molecules in HNSCC.  
 In vitro, GZ17 -formulations showed significant anti-cancer effects. This prompted 
a need to assess the mechanism of action and the additive effects observed. To test 
this, a phospho-protein array was employed to determine if signaling molecules were 
being modulated by GZ17 treatments. Phosphorylation of several signaling proteins 
including EGFR, and several downstream molecules including Src, ERK1/2, Akt, STAT-
2, Chk-2 were significantly diminished in GZ17-treated HNSCC (ED50 dose) (Fig. 4-4 A, 
B). Other signaling pathways were represented in the array and some showed a modest 
decrease in phosphorylation (not shown). We focused on EGFR and its downstream 
molecules as these were most consistently and significantly decreased in the GZ17-
6.02 treatment group. Further, EGFR is overexpressed and highly characterized in 
HNSCC; contributing to inhibition of apoptosis, activation of proliferation and 
angiogenesis, and radiotherapy resistance [85]. These signaling molecules are 
important modulators of HNSCC proliferation, migration, and survival. 
 ERK1/2 is a regulator of HNSCC proliferation, and increased levels are 
associated with advanced disease [86]. An immunoblot of pERK1/2 at both a short time 
interval when induced by EGF (5 min) and a long interval (72hr) validated the phosphor-
protein array (Fig. 4-4 C). These data demonstrate that GZ17–6.02 inhibits the 












































Figure 4-4. (A) HNSCC cells (OSC19; 2 × 105 cells) were treated with vehicle control or ED50 
concentrations of GZ17-6.02, -05.00 or –S for 48 h. Representative dot-blot image from phospho-kinase 
array. (B) Densitometric analyses of dot-blot image signals from GZ17 treated lysates normalized to those 
from vehicle control and represented as fold change in protein levels. The graph shows sum data from 
two individual experiments. Error bars represent ± SEM. (C) HNSCC cells (OSC19; 2 × 105 cells) were 
treated with ED50 concentrations of GZ17-6.02, -05.00, –S or vehicle control for 72 h. Immunoblot was 
implemented for phospho-ERK1/2 and total ERK1/2 as loading control. Image is illustrative of three 
individual experimental repeats. Densitometric analyses of signals from immunoblots normalized to 
loading control and represented as fold change in protein levels relative to vehicle control treated cells. 
Error bars represent ± SEM [79]. 
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GZ17-6.02 agents bind with affinity to EGFR, Akt1, and ERK1/2. 
 Docking analysis was performed to investigate the mechanisms of GZ17-6.02 on 
specific targets. Curcumin and harmine, along with their metabolites, displayed high 
binding affinity to several distinct binding sties on EGFR, Akt1, and ERK1-2 (Fig 4-5). 
Curcumin presented as the best binding agent at -6.6 Kcal/mol to Akt1 and -6.5 
Kcal/mol to EGFR. Isovanillin did not show significant binding to the assessed targets. 
Simultaneous interaction to the target may explain the enhanced efficacy of the 
combination.  
GZ17-6.02 enhances cisplatin efficacy.  
 The standard of care chemotherapy for HNSCC patients is platinum-based [36]. 
However, cisplatin resistant-tumors are a common occurrence in HNSCC therapy. 
HNSCC cell survival was tested against the combination of GZ17-6.02 (ED50) with 
cisplatin (4.0 μM). The combination of cisplatin with GZ17-6.02 significantly reduced 
HNSCC cell survival as compared to either treatments alone (p < 0.0008, Fig. 4-6 A–C). 
A combination of radiation and GZ17-6.02 was found to have greater cytotoxicity than 3, 
6, or 9 Gy of radiation alone (Fig. 4-6 D), with no additive benefit of radiation in 
combination. These data demonstrate GZ17-6.02 treatment potentiates the effects of 







Figure 4-5: Curcumin and harmine bind with high affinity to distinct sites on 
ERK1, EGFR, and Akt-1 
 





































Figure 4-5. Binding conformation of top ranked docked poses of (A,C,E) curcumin and (B,D,F) harmine 






 Figure 4-6: The combination of GZ17-6.02 with cisplatin or radiation potentiates 
HNSCC cytotoxicity  
 
 

























Figure 4-6: A) OSC19, (B) HN5, and (C) UM-SCC-1; (2 × 103 cells/well) in triplicate were treated with 
their respective ED50 concentrations of GZ17-6.02, cisplatin (4 μM), combination of both GZ17-6.02 and 
cisplatin, or vehicle control for 72 h. Cell survival was determined by CyQUANT assay. Obtained values 
were normalized to vehicle control and represented by fold change in cell survival. Sum data represents 










GZ17-6.02 effectively inhibits HNSCC tumor growth in vivo.  
 GZ17 formulations had previously never been tested in animal models. To 
assess the efficacy of GZ17 in vivo, OSC19 tumors were injected in athymic nude mice 
with GZ17 formulations via intratumoral injection(15mg/kg/day) . Of all treatment 
groups, GZ17-6.02 was displayed the lowest increase in tumor volume (p<0.001, Fig. 4-
7 A). A syngeneic SCC model was used to determine GZ17-6.02 in an 
immunocompetent host. SCCvII/SF syngeneic tumors are highly aggressive, requiring 
higher doses for testing. Therefore, GZ17-6.02 was given by oral gavage at a greater 
dose (100mg/kg/day). A significant decrease in tumor volume was seen by GZ17-6.02 
treated mice (p<0.001, Fig 4-7 B). GZ17-6.02 treated mice demonstrated no abnormal 
behavior secondary to therapy; mice were active, curious, and behaved normally. 
Likewise, there was no difference in mouse weights between treatment groups (Fig. 4-7 
C), and no adverse effects from treatment was evident. This shows GZ17-6.02 to be 
well tolerated in mouse models.  
 The response of GZ17-6.02 in patient-derived xenograft (PDX) tumors was 
assessed. GZ17-6.02 was given by oral gavage at a lower dose of 30 mg/kg/day for 8 
days. The dose was then increased to 50mg/kg/day for the remaining duration of the 
study to improve the antitumoral response. GZ17-6.02 demonstrated significant anti-
tumor effects compared to the vehicle control treated mice (<0.01, Fig. 4-7 D). 
Additionally, immunoblot was employed on GZ17-6.02 treated tumors to evaluate 
pERK1/2. Mice treated with GZ17-6.02 showed a significant decrease in pERK1/2 
(p=0.0006 Fig. 4-7 E). GZ17-6.02 has demonstrated substantial anti-tumor effects in 
HNSCC preclinical models. 
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 Figure 4-7: GZ17-6.02 demonstrates significant HNSCC antitumor effects in vivo  
 






























Figure 6. (A) HNSCC cells (OSC19; 1 × 106 cells) were injected subcutaneously on the flanks of athymic 
nude-Foxn1nu mice. Five mice per group were treated intratumorally with vehicle control (saline), or 15 
mg/kg/d of GZ17-06.02, GZ17-5.0 or GZ17-S for three weeks. The graph shows tumor volumes 
measured with a vernier caliper over the course of the experiment. Error bars represent ± SEM. (B) 
Immunocompetent SCC/vII tumor bearing C3H mice were treated with GZ17-6.02 (100 mg/kg/day in 1% 
carboxymethylcellulose (CMC) suspension) or VC (1% CMC) by oral gavage (N = 10/group). The graph 
represents tumor volumes measured with a Vernier caliper over the course of the experiment. (C) 
Immunocompetent were administered via oral gavage either GZ17-6.02 (ED50) or vehicle control and 
weighed incrementally for 15 days. (D) Patient-derived HNSCC tumor masses (35 mg/site) were 
surgically implanted subcutaneously on both flanks of athymic nude-Foxn1nu mice. Ten mice per group 
were treated by oral gavage with GZ17-6.02 (30 mg/kg/d for first 7 days, and dose increased to 50 
mg/kg/d to improve antitumoral effect) or vehicle control (saline) for 19 days. The graph represents 
fractional tumor volumes over the course of the experiment. (E) Representative immunoblot of patient-
derived xenograft lysates demonstrates decrease in p-ERK1/2 levels. Densitometric analysis of p-ERK1/2 
relative to density of loading control (β-tubulin) of GZ17-6.02 treated tumors (n = 8) compared relative to 
vehicle control (n = 8) were graphed. Error bars represent ± SEM. 
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Chapter V: Discussion  
Sections of this chapter have been previously published as an open access article and 
are included here with adaptations with permission.  Vishwakarma, V., et al., Potent 
Antitumor Effects of a Combination of Three Nutraceutical Compounds. Sci Rep, 2018. 
8(1): p. 12163. 
 Few studies have studied the combination of synthetic plant compounds to 
potentiate their effects [69], and no studies have previously been published examining a 
synthetic plant compound combination therapy for HNSCC. A combination therapy of 
known anti-cancer synthetic plant compounds could have additive antitumor effects. 
However, it is previously known that overly complex combinations of natural compounds 
may actually worsen the expected antitumor effects [87]. In this work, the plant 
compound curcumin, which is previously shown to have efficacy in combination 
formulations, was combined with two other plant compounds indicated to have anti-
tumor activity, Arum palaestinum and Peganum harmala. The results obtained in this 
work rationalize the combination of GZ17-6.02, a mix of isovanillin, harmine, and 
curcumin as a more potent combination than single agents when evaluating anti-tumor 
efficacy. This, in tandem with a recent boon in plant derived compound research 
showing efficacy and safety[88], endorses GZ17-6.02 for further investigation.  
 GZ17-6.02 induced significant apoptosis via caspase-3, and inhibited 
phosphorylation of ERK1/2. This verifies previous findings that curcumin benefits 
cisplatin HNSCC treatment efficacy by increasing caspase 3/9 activity [89], and in 
breast cancer curcumin reduces proliferation by inhibiting phosphorylation of ERK1/2. 
Likewise, curcumin demonstrates improved effects when in combination with other 
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natural compounds or known drugs in other cancer types [69]. The production of 
reactive oxygen species is important to the development of macrophage-mediated 
inflammation-induced tumor progression. Importantly, curcumin is known to reduce the 
production of reactive oxygen species in macrophages [90]. Additionally, curcumin has 
been demonstrated to stimulate macrophages to the tumor inhibitory M1 phenotype 
[91]. The MMD model revealed significant reduction in macrophage volume when 
treated with GZ17-6.02. GZ17-6.02 demonstrated the ability to reduce macrophages 
viability and infiltration into tumor in vitro. GZ17-6.02 was also shown to reduce HNSCC 
proliferation and angiogenesis. This work corroborates previous work that demonstrated 
β-carboline (naturally occurring in harmine) to have anti-tumor and anti-angiogenic 
effects via intercalation of DNA, damaging it, and inducing tumor-suppressor p53 [92, 
93]. Isovanillin has been proposed as a potential antitumor compound [72], and is 
known for its antioxidant effects  
 Cancer is vastly complex and presents with many different oncogenic pathways. 
This makes the ability of a drug to possess multiple targets highly desirable [94]. GZ17-
6.02 demonstrated this multi-target ability by reducing Akt1, EGFR, and ERK1/2 and 
has high binding affinity to these targets. Additionally, Akt1 and EGFR mutations can 
induce chemotherapy resistance [95, 96]. As cisplatin resistance is a common 
occurrence in HNSCC treatment, it would be advantageous for a compound to target 
multiple molecules in a signaling pathway potentially relieving cisplatin resistance. This 
work reveals GZ17-6.02 to potentiate the effects of cisplatin. Feng et al. have previously 
shown that inhibition of Chk-2 enhanced the sensitivity of HNSCC to radiotherapy and 
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cisplatin [97]. This work shows that GZ17-6.02 deactivated Chk-2, which may explain 
the potentiated effect of this compound with cisplatin. 
 Many plant derived compounds are commonly limited by poor bioavailability. 
GZ17-6.02 seems to have overcome this. In vivo, GZ17-6.02 decreased HNSCC 
xenograft tumors, syngeneic SCC tumors in an immunocompetent mouse model, and 
patient-derived xenografts of HNSCC tumors. The initial dose of GZ17-6.02 was 
15mg/kg/day via intratumoral injection was increased to 100mg/kg/day in the syngeneic 
model to establish in vivo dose. In the PDX model, 30mg/kg/day of GZ17-6.02 was 
administered via oral gavage. However, to improve tumor response the dose was 
increased to 50mg/kg/day on the eighth day. The mice tolerated all GZ17 formulations 
well, exhibiting no abnormal behavior, and maintaining body weight between different 
treatments of GZ17. Furthermore, in vitro analysis of non-cancerous Het1A cell line 
displayed a higher ED50 compared to cancer lines tested. 
 GZ17-6.02 displayed significant potentiated effects of standard of care therapy in 
both in vitro and in vivo animal models. In vivo phospho-ERK1/2 immunoblot revealed 
that GZ17-6.02 reduced p-ERK1/2 levels, supporting the in vitro model of phosphor- 
ERK1/2 reduction and docking analysis of ERK1/2.  
Limitations 
 
 No testing of separate components of GZ17-6.02 were tested in vivo. However, 
the single components alone were not significantly potent compared to GZ17-6.02 in 
vitro. Further, there is little clinical efficacy of the single compounds. There were no 
observed toxicities to GZ17-6.02 in the in vivo models tested. 
 35 
 Therefore, the evidence presented proposes GZ17-6.02 to possess anti-tumor 
effects in HNSCC in preclinical models, and lay the foundation for future clinical trials 
using this treatment.  
 
Supplementary Table 1 
Supplemental Table 1: Synthetic components in GZ17-0.5.00 and GZ17-0.6.02 
GZ17-05.00 
Component µg/mL of water 
Isovanillin 5.882 
Beta-sitosterol 11.765 
Linolenic Acid 4.059 
Harmine 9.941 
Hydroxymethyl furfural 5.529 
Piperonal 2.000 
Citraconic anhydride 2.235 
Methylpyroglutamate 2.529 
Curcumin 7.529 
Benzyl nitrile 4.412 
Limonene 2.941 
GZ17-06.02 
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